Cargando…
T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer
The immune environment is a determinant of whether patients with cancer can benefit from immunotherapy. Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with different types of malignancies and have initiated a transformation in tumor therapy. However, some patients cannot...
Autores principales: | Wei, Xiaoying, Gu, Ling, Heng, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751340/ https://www.ncbi.nlm.nih.gov/pubmed/33376522 http://dx.doi.org/10.3892/ol.2020.12350 |
Ejemplares similares
-
Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020) -
Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023) -
Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer
por: Lu, Xiaojuan, et al.
Publicado: (2022) -
Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021) -
Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer
por: Choi, Myeong Geun, et al.
Publicado: (2020)